论文部分内容阅读
目的研究125I标记抗C-erbB-2单克隆抗体ICR12（简称125I-ICR12）及正常小鼠IgG（简称125I-mIgG）在荷入乳腺癌探鼠体内的分布，为放射免疫显像（RII）及临床应用提供依据。方法每鼠尾静脉注射抗体92．5KBq／0．1ml，于注射后24、48、96、120／小时分批处死，测定肿瘤和血液、肝、肺等重要脏器的单位重量放射性比值（T／NT）、各组织摄取百分比（％ID／g）及定位指数（LI）。结果125I-ICR12注射后24～120／小时内，肿瘤部位出现选择性放射性浓聚；T／NT在120／小时最高，为19．374。125I-mlgG未出现放射性浓聚，呈全身分布。结论ICR12在荷人乳腺癌裸鼠体内，对过度表达C-erbB-2的乳腺癌具有亲和力，可望用作乳腺癌诊断、预后判断的导向载体。
Objective To study the distribution of 125I-labeled anti-C-erbB-2 monoclonal antibody ICR12 (abbreviated as 125I-ICR12) and normal mouse IgG (abbreviated as 125I-mIgG) in breast cancer mice. The radioimmunoimaging (RII) imaging was performed. And provide the basis for clinical application. Methods 92.5 KBq/0.1 ml of antibody was injected into the tail vein of each rat. They were killed in batches at 24, 48, 96, and 120/hour after injection. The specific radioactivity per unit weight of tumor and blood, liver, lung, and other organs was measured. /NT), Percentage of Ingestion by Each Organization (%ID/g) and Positioning Index (LI). RESULTS Selective radioactivity accumulation occurred at tumor sites within 24 to 120 hours after injection of 125I-ICR12; T/NT was highest at 120/hr, which was 19.374. 125I-mlgG did not show radioactivity concentration and showed systemic distribution. Conclusion ICR12 has a high affinity for breast cancer over-expressing C-erbB-2 in nude mice bearing human breast cancer, which is expected to be used as a guide for diagnosis and prognosis of breast cancer.